Related Experiment Video

Updated: Mar 7, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Advances in oral anticoagulation therapy - What's in the pipeline?

P S S Rao1, T Burkart2

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, The University of Findlay, Findlay, OH 45840, USA.

Blood Reviews
|February 11, 2017
PubMed

Insights

Newer factor Xa inhibitors offer a convenient pathway for venous thromboembolic (VTE) event management. Early trials suggest darexaban, betrixaban, and nokxaban show promise for safer anticoagulation.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Venous thromboembolic (VTE) events affect approximately 900,000 individuals annually in the U.S.
  • Traditional VTE treatments necessitate regular laboratory monitoring for safety and efficacy.
  • Activated factor X (FXa) inhibition presents a more convenient VTE management strategy.

Purpose of the Study:

  • To review pharmacokinetic, pharmacodynamic, and early safety/efficacy data of three developing FXa inhibitors.
  • To assess the potential advantages of novel FXa inhibitors over existing therapies.
  • To explore the therapeutic promise of darexaban, betrixaban, and nokxaban.

Main Methods:

  • Review of early-phase (Phase I and II) clinical trial data.
  • Analysis of pharmacokinetic and pharmacodynamic profiles.
  • Evaluation of preliminary safety and efficacy outcomes.

Main Results:

  • The three investigated FXa inhibitors (darexaban, betrixaban, nokxaban) demonstrate promising early-phase results.
  • Novel properties may offer improved safety and efficacy compared to traditional anticoagulants.
  • Pharmacokinetic and pharmacodynamic data suggest potential for optimized VTE treatment.

Conclusions:

  • Darexaban, betrixaban, and nokxaban represent promising advancements in FXa inhibitor development.
  • These agents may offer advantages in managing VTE with potentially fewer adverse effects.
  • Further clinical trials are warranted to confirm the therapeutic potential of these novel anticoagulants.
Keywords:
Activated factor X inhibitorAnticoagulation therapyFactor XaNovel oral anticoagulantsVenous thromboembolism

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
108
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
80